{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:30:18Z","timestamp":1787913018498,"version":"build-2784847793"},"reference-count":45,"publisher":"Bioscientifica","issue":"9","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:p>\n                    Malignant pheochromocytomas (PHEOs)\/paragangliomas (PGLs) are rare tumors for which clinical outcomes remain poorly defined and therapeutic options are limited. Approximately 27% carry pathogenic germline succinate dehydrogenase (\n                    <jats:italic>SDHx<\/jats:italic>\n                    ) mutations; the presence of such mutations has been correlated with response to temozolomide (TMZ). We aimed to investigate the association between germline mutations in\n                    <jats:italic>SDHx<\/jats:italic>\n                    and response to TMZ. We retrospectively identified patients with metastatic malignant PHEO\/PGLs treated with TMZ- based chemotherapy at Dana-Farber Cancer Institute between 2003 and 2020. The correlation between response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and PET Response Criteria in Solid Tumors (PERCIST) and the presence of\n                    <jats:italic>SDHx<\/jats:italic>\n                    mutations in the germline and tumor was evaluated. Nineteen patients received TMZ. Seventeen underwent germline assessment: 9 (53%) carried a pathogenic SDHx germline mutation. Fifteen patients were evaluable for response by RECIST 1.1: 6 (40%) partial response, 4 (27%) stable disease, and 5 (33%) progressive disease. Overall median progression-free survival was 2.2 years. Three-year overall survival (OS) was 58%. Median PFS was 1.3 years and 5.5 years for carriers and non-carriers, respectively and OS was 1.5 years and not estimable for carriers and non-carriers, respectively. The response by PERCIST criteria in nine patients correlated with the RECIST 1.1 assessment. Our series represents one of the largest analyses of patients with malignant PHEOs\/PGLs treated with TMZ who have available germline data. The incidence of pathogenic germline\n                    <jats:italic>SDHx<\/jats:italic>\n                    mutations was similar to what has been previously published, though our analysis suggests that there may be a limited association between response to TMZ and pathogenic germline\n                    <jats:italic>SDHx<\/jats:italic>\n                    mutations.\n                  <\/jats:p>","DOI":"10.1530\/erc-21-0392","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T09:32:24Z","timestamp":1655890344000},"page":"533-544","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":24,"title":["SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma"],"prefix":"10.1530","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-2994","authenticated-orcid":true,"given":"Kimberly","family":"Perez","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jacene","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L","family":"Hornick","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Vaz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren K","family":"Brais","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9062-8744","authenticated-orcid":true,"given":"Holly","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Baddoo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-7732","authenticated-orcid":true,"given":"Kristina","family":"Astone","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-3756","authenticated-orcid":true,"given":"Edward D","family":"Esplin","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6631-4174","authenticated-orcid":true,"given":"John","family":"Garcia","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-930X","authenticated-orcid":true,"given":"Daniel M","family":"Halperin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8556-3977","authenticated-orcid":true,"given":"Matthew H","family":"Kulke","sequence":"additional","affiliation":[{"name":"Section of Hematology and Oncology, Boston University and Boston Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Oncologist","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1634\/theoncologist.2008-0043","article-title":"Pheochromocytoma: current approaches and future directions","volume":"13","author":"Adler","year":"2008","unstructured":"Adler JTMeyer-Rochow GYChen HBenn DERobinson BGSippel RSSidhu SB2008Pheochromocytoma: current approaches and future directions. Oncologist13779\u2013793. (https:\/\/doi.org\/10.1634\/theoncologist.2008-0043)10.1634\/theoncologist.2008-0043"},{"key":"bib2","series-title":"Surgery","first-page":"1009","article-title":"DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors","volume":"102","author":"Altimari","year":"1987","unstructured":"Altimari AFBadrinath KReisel HJPrinz RA1987DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors. Surgery1021009\u20131017."},{"key":"bib3","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","article-title":"Genetic testing in pheochromocytoma or functional paraganglioma","volume":"23","author":"Amar","year":"2005","unstructured":"Amar LBertherat JBaudin EAjzenberg CBressac-De Paillerets BChabre OChamontin BDelemer BGiraud SMurat A, 2005Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology238812\u20138818. (https:\/\/doi.org\/10.1200\/JCO.2005.03.1484)10.1200\/JCO.2005.03.1484"},{"key":"bib4","series-title":"Annals of Internal Medicine","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","unstructured":"Averbuch SDSteakley CSYoung RCGelmann EPGoldstein DSStull RKeiser HR1988Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Annals of Internal Medicine109267\u2013273. (https:\/\/doi.org\/10.7326\/0003-4819-109-4-267)10.7326\/0003-4819-109-4-267"},{"key":"bib5","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1210\/jc.2005-1862","article-title":"Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes","volume":"91","author":"Benn","year":"2006","unstructured":"Benn DEGimenez-Roqueplo APReilly JRBertherat JBurgess JByth KCroxson MDahia PLElston MGimm O, 2006Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes. Journal of Clinical Endocrinology and Metabolism91827\u2013836. (https:\/\/doi.org\/10.1210\/jc.2005-1862)10.1210\/jc.2005-1862"},{"key":"bib6","series-title":"Kidney International","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/ki.1991.244","article-title":"Pheochromocytoma: new concepts and future trends","volume":"40","author":"Bravo","year":"1991","unstructured":"Bravo EL1991Pheochromocytoma: new concepts and future trends. Kidney International40544\u2013556. (https:\/\/doi.org\/10.1038\/ki.1991.244)10.1038\/ki.1991.244"},{"key":"bib7","series-title":"Hormone and Metabolic Research","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1055\/s-0029-1224135","article-title":"Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report","volume":"41","author":"Bravo","year":"2009","unstructured":"Bravo ELKalmadi SRGill I2009Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. Hormone and Metabolic Research41703\u2013706. (https:\/\/doi.org\/10.1055\/s-0029-1224135)10.1055\/s-0029-1224135"},{"key":"bib8","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","unstructured":"Brouwers FMEisenhofer GTao JJKant JAAdams KTLinehan WMPacak K2006High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. Journal of Clinical Endocrinology and Metabolism914505\u20134509. (https:\/\/doi.org\/10.1210\/jc.2006-0423)10.1210\/jc.2006-0423"},{"key":"bib9","series-title":"Journal of Cancer","first-page":"80","article-title":"Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST","volume":"1","author":"Costelloe","year":"2010","unstructured":"Costelloe CMChuang HHMadewell JEUeno NT2010Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. Journal of Cancer180\u201392. (https:\/\/doi.org\/10.7150\/jca.1.80)"},{"key":"bib10","series-title":"Genes, Chromosomes and Cancer","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/gcc.20834","article-title":"Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors","volume":"50","author":"Cunningham","year":"2011","unstructured":"Cunningham JLD\u00edaz De St\u00e5hl TSj\u00f6blom TWestin GDumanski JPJanson ET2011Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes, Chromosomes and Cancer5082\u201394. (https:\/\/doi.org\/10.1002\/gcc.20834)10.1002\/gcc.20834"},{"key":"bib11","series-title":"F1000Research","article-title":"Case Report: propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma","volume":"6","author":"D\u00edaz-Castellanos","year":"2017","unstructured":"D\u00edaz-Castellanos MAG\u00f3mez De las heras KVD\u00edaz-Redondo Tgonz\u00e1lez-Flores EAlbi\u00f1ana VBotella LM2017Case Report: propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma. F1000Research6 2087. (https:\/\/doi.org\/10.12688\/f1000research.13185.1)"},{"key":"bib12","series-title":"Kidney Cancer","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/KCA-190075","article-title":"Utility of FDG-PET\/CT in patients with advanced renal cell carcinoma with osseous metastases: comparison with CT and 99mTc-MDP bone scan in a prospective clinical trial","volume":"3","author":"Dibble","year":"2019","unstructured":"Dibble EHKravets SCheng SSakellis CGray KPAbbott ABoss\u00e9 DPomerantz MMMcgregor BAHarshman LC, 2019Utility of FDG-PET\/CT in patients with advanced renal cell carcinoma with osseous metastases: comparison with CT and 99mTc-MDP bone scan in a prospective clinical trial. Kidney Cancer3241\u2013251. (https:\/\/doi.org\/10.3233\/KCA-190075)10.3233\/KCA-190075"},{"key":"bib13","series-title":"Clinical Genetics","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/cge.12315","article-title":"A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes","volume":"86","author":"Eggington","year":"2014","unstructured":"Eggington JMBowles KRMoyes KManley SEsterling LSizemore SRosenthal ETheisen ASaam JArnell C, 2014A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clinical Genetics86229\u2013237. (https:\/\/doi.org\/10.1111\/cge.12315)10.1111\/cge.12315"},{"key":"bib14","series-title":"Endocrine-Related Cancer","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1677\/erc.1.00829","article-title":"Malignant pheochromocytoma: current status and initiatives for future progress","volume":"11","author":"Eisenhofer","year":"2004","unstructured":"Eisenhofer GBornstein SRBrouwers FMCheung NKDahia PLDe Krijger RRGiordano TJGreene LAGoldstein DSLehnert H, 2004Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer11423\u2013436. (https:\/\/doi.org\/10.1677\/erc.1.00829)10.1677\/erc.1.00829"},{"key":"bib15","series-title":"Anti-Cancer Drugs","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/CAD.0000000000000570","article-title":"Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma","volume":"29","author":"Ferrara","year":"2018","unstructured":"Ferrara AMLombardi GPambuku AMeringolo DBertorelle RNardin MSchiavi FIacobone MOpocher GZagonel V, 2018Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. Anti-Cancer Drugs29102\u2013105. (https:\/\/doi.org\/10.1097\/CAD.0000000000000570)10.1097\/CAD.0000000000000570"},{"key":"bib16","series-title":"Annals of the New York Academy of Sciences","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1196\/annals.1353.050","article-title":"Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)","volume":"1073","author":"Fitzgerald","year":"2006","unstructured":"Fitzgerald PAGoldsby REHuberty JPPrice DCHawkins RAVeatch JJdela cruz FJahan TMLinker CADamon L, 2006Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Annals of the New York Academy of Sciences1073465\u2013490. (https:\/\/doi.org\/10.1196\/annals.1353.050)10.1196\/annals.1353.050"},{"key":"bib17","series-title":"European Journal of Nuclear Medicine and Molecular Imaging","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","article-title":"131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma","volume":"35","author":"Gedik","year":"2008","unstructured":"Gedik GKHoefnagel CABais EOlmos RA2008131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging35725\u2013733. (https:\/\/doi.org\/10.1007\/s00259-007-0652-6)10.1007\/s00259-007-0652-6"},{"key":"bib18","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","unstructured":"Gonias SGoldsby RMatthay KKHawkins RPrice DHuberty JDamon LLinker CSznewajs AShiboski S, 2009Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. Journal of Clinical Oncology274162\u20134168. (https:\/\/doi.org\/10.1200\/JCO.2008.21.3496)10.1200\/JCO.2008.21.3496"},{"key":"bib19","series-title":"Cancer Cell","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ccell.2018.12.011","article-title":"Mutational signature analysis reveals NTHL1 deficiency to cause a multi-tumor phenotype","volume":"35","author":"Grolleman","year":"2019","unstructured":"Grolleman JEDe Voer RMElsayed FANielsen MWeren RDAPalles CLigtenberg MJLVos JRten broeke SWDe Miranda NFCC, 2019Mutational signature analysis reveals NTHL1 deficiency to cause a multi-tumor phenotype. Cancer Cell35256.e5\u2013266.e5. (https:\/\/doi.org\/10.1016\/j.ccell.2018.12.011)10.1016\/j.ccell.2018.12.011"},{"key":"bib20","series-title":"International Journal of Cancer","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","unstructured":"Hadoux JFavier JScoazec JYLeboulleux SAl Ghuzlan ACaramella CD\u00e9andreis DBorget ILoriot CChougnet C, 2014SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer1352711\u20132720. (https:\/\/doi.org\/10.1002\/ijc.28913)10.1002\/ijc.28913"},{"key":"bib21","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"Hegi","year":"2008","unstructured":"Hegi MELiu LHerman JGStupp RWick WWeller MMehta MPGilbert MR2008Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. Journal of Clinical Oncology264189\u20134199. (https:\/\/doi.org\/10.1200\/JCO.2007.11.5964)10.1200\/JCO.2007.11.5964"},{"key":"bib22","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.23812","article-title":"Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients","volume":"113","author":"Huang","year":"2008","unstructured":"Huang HAbraham JHung EAverbuch SMerino MSteinberg SMPacak KFojo T2008Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer1132020\u20132028. (https:\/\/doi.org\/10.1002\/cncr.23812)10.1002\/cncr.23812"},{"key":"bib23","series-title":"Breast Cancer Research and Treatment","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10549-020-05631-4","article-title":"Discrepancy between FDG-PET\/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning","volume":"181","author":"Jacene","year":"2020","unstructured":"Jacene HADipiro PJBellon JHu JCheng SCWarren LSchlosnagle ENakhlis FRosenbluth JMYeh E, 2020Discrepancy between FDG-PET\/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Research and Treatment181383\u2013390. (https:\/\/doi.org\/10.1007\/s10549-020-05631-4)10.1007\/s10549-020-05631-4"},{"key":"bib24","series-title":"European Journal of Nuclear Medicine and Molecular Imaging","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","unstructured":"Janssen IChen CCMillo CMLing ATaieb DLin FIAdams KTWolf KIHerscovitch PFojo AT, 2016PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging431784\u20131791. (https:\/\/doi.org\/10.1007\/s00259-016-3357-x)10.1007\/s00259-016-3357-x"},{"key":"bib25","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","unstructured":"Kulke MHStuart KEnzinger PCRyan DPClark JWMuzikansky AVincitore MMichelini AFuchs CS2006Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology24401\u2013406. (https:\/\/doi.org\/10.1200\/JCO.2005.03.6046)10.1200\/JCO.2005.03.6046"},{"key":"bib26","series-title":"JAMA","first-page":"1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best?","volume":"287","author":"Lenders","year":"2002","unstructured":"Lenders JWPacak KWalther MMLinehan WMMannelli MFriberg PKeiser HRGoldstein DSEisenhofer G2002Biochemical diagnosis of pheochromocytoma: which test is best?JAMA2871427\u20131434. (https:\/\/doi.org\/10.1001\/jama.287.11.1427)"},{"key":"bib27","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","unstructured":"Lenders JWEisenhofer GMannelli MPacak K2005Phaeochromocytoma. Lancet366665\u2013675. (https:\/\/doi.org\/10.1016\/S0140-6736(0567139-5)10.1016\/S0140-6736(05)67139-5"},{"key":"bib28","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","unstructured":"Middleton MRGrob JJAaronson NFierlbeck GTilgen WSeiter SGore MAamdal SCebon JCoates A, 2000Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology18158\u2013166. (https:\/\/doi.org\/10.1200\/JCO.2000.18.1.158)10.1200\/JCO.2000.18.1.158"},{"key":"bib29","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]","volume":"55","author":"Mukherjee","year":"2001","unstructured":"Mukherjee JJKaltsas GAIslam NPlowman PNFoley RHikmat JBritton KEJenkins PJChew SLMonson JP, 2001Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clinical Endocrinology5547\u201360. (https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01309.x)10.1046\/j.1365-2265.2001.01309.x"},{"key":"bib30","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","unstructured":"Neumann HPHBausch BMcwhinney SRBender BUGimm OFranke GSchipper JKlisch JAltehoefer CZerres K, 2002Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine3461459\u20131466. (https:\/\/doi.org\/10.1056\/NEJMoa020152)10.1056\/NEJMoa020152"},{"key":"bib31","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1530\/EJE-11-1098","article-title":"A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine","volume":"166","author":"Nozi\u00e8res","year":"2012","unstructured":"Nozi\u00e8res CWalter TJoly MOGiraud SScoazec JYBorson-Chazot FSimon CRiou JPLombard-Bohas C2012A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine. European Journal of Endocrinology1661107\u20131111. (https:\/\/doi.org\/10.1530\/EJE-11-1098)10.1530\/EJE-11-1098"},{"key":"bib32","series-title":"Genetics in Medicine","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/gim.2017.37","article-title":"Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria","volume":"19","author":"Nykamp","year":"2017","unstructured":"Nykamp KAnderson MPowers MGarcia JHerrera BHo YYKobayashi YPatil NThusberg JWestbrook M, 2017Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. Genetics in Medicine191105\u20131117. (https:\/\/doi.org\/10.1038\/gim.2017.37)10.1038\/gim.2017.37"},{"key":"bib33","series-title":"European Journal of Cancer","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","unstructured":"Patel PMSuciu SMortier LKruit WHRobert CSchadendorf DTrefzer UPunt CJDummer RDavidson N, 2011Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). European Journal of Cancer471476\u20131483. (https:\/\/doi.org\/10.1016\/j.ejca.2011.04.030)10.1016\/j.ejca.2011.04.030"},{"key":"bib34","series-title":"European Journal of Nuclear Medicine and Molecular Imaging","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00259-017-3687-3","article-title":"Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments","volume":"44","author":"Pinker","year":"2017","unstructured":"Pinker KRiedl CWeber WA2017Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. European Journal of Nuclear Medicine and Molecular Imaging4455\u201366. (https:\/\/doi.org\/10.1007\/s00259-017-3687-3)10.1007\/s00259-017-3687-3"},{"key":"bib35","series-title":"Genetics in Medicine","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","unstructured":"Richards SAziz NBale SBick DDas SGastier-Foster JGrody WWHegde MLyon ESpector E, 2015Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine17405\u2013424. (https:\/\/doi.org\/10.1038\/gim.2015.30)10.1038\/gim.2015.30"},{"key":"bib36","series-title":"Surgery","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0039-6060(03)00426-4","article-title":"Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma","volume":"134","author":"Safford","year":"2003","unstructured":"Safford SDColeman REGockerman JPMoore JFeldman JMLeight GSTyler DSOlson Jr. JA2003Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery134956\u2013962; discussion 962\u2013963. (https:\/\/doi.org\/10.1016\/s0039-6060(0300426-4)10.1016\/S0039-6060(03)00426-4"},{"key":"bib37","series-title":"JAMA Oncology","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients With hereditary cancer syndrome","volume":"7","author":"Samadder","year":"2021","unstructured":"Samadder NJRiegert-Johnson DBoardman LRhodes DWick MOkuno SKunze KLGolafshar MUson Jr. PLSMountjoy L, 2021Comparison of universal genetic testing vs guideline-directed targeted testing for patients With hereditary cancer syndrome. JAMA Oncology7230\u2013237. (https:\/\/doi.org\/10.1001\/jamaoncol.2020.6252)10.1001\/jamaoncol.2020.6252"},{"key":"bib38","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1210\/jc.2002-021251","article-title":"A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines","volume":"88","author":"Sawka","year":"2003","unstructured":"Sawka AMJaeschke RSingh RJYoung Jr. WF2003A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. Journal of Clinical Endocrinology and Metabolism88553\u2013558. (https:\/\/doi.org\/10.1210\/jc.2002-021251)10.1210\/jc.2002-021251"},{"key":"bib39","series-title":"Journal of the National Comprehensive Cancer Network","doi-asserted-by":"publisher","first-page":"693","DOI":"10.6004\/jnccn.2018.0056","article-title":"NCCN Guidelines Insights: neuroendocrine and adrenal tumors, version 2.2018","volume":"16","author":"Shah","year":"2018","unstructured":"Shah MHGoldner WSHalfdanarson TRBergsland EBerlin JDHalperin DChan JKulke MHBenson ABBlaszkowsky LS, 2018NCCN Guidelines Insights: neuroendocrine and adrenal tumors, version 2.2018. Journal of the National Comprehensive Cancer Network16693\u2013702. (https:\/\/doi.org\/10.6004\/jnccn.2018.0056)10.6004\/jnccn.2018.0056"},{"key":"bib40","series-title":"Hormones and Cancer","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","unstructured":"Tanabe ANaruse MNomura KTsuiki MTsumagari AIchihara A2013Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Hormones and Cancer4103\u2013110. (https:\/\/doi.org\/10.1007\/s12672-013-0133-2)10.1007\/s12672-013-0133-2"},{"key":"bib41","series-title":"Clinical Medicine Insights: Oncology","first-page":"1179554918763367","article-title":"Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature","volume":"12","author":"Tena","year":"2018","unstructured":"Tena IGupta GTajahuerce MBenavent MCifri\u00e1n MFalcon AFonfria Mdel olmo MReboll RConde A, 2018Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature. Clinical Medicine Insights: Oncology121179554918763367. (https:\/\/doi.org\/10.1177\/1179554918763367)"},{"key":"bib42","series-title":"Journal of the National Cancer Institute","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","unstructured":"Timmers HJChen CCCarrasquillo JAWhatley MLing AEisenhofer GKing KSRao JUWesley RAAdams KT, 2012Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. Journal of the National Cancer Institute104700\u2013708. (https:\/\/doi.org\/10.1093\/jnci\/djs188)10.1093\/jnci\/djs188"},{"key":"bib43","series-title":"Frontiers in Endocrinology","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fendo.2020.00061","article-title":"Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma\u2014case report and review of the literature","volume":"11","author":"Tong","year":"2020","unstructured":"Tong ALi MCui YMa XWang HLi Y2020Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma\u2014case report and review of the literature. Frontiers in Endocrinology1161. (https:\/\/doi.org\/10.3389\/fendo.2020.00061)10.3389\/fendo.2020.00061"},{"issue":"Supplement 1","key":"bib44","series-title":"Journal of Nuclear Medicine","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","unstructured":"Wahl RLJacene HKasamon YLodge MA2009From RECIST to PERCIST: evolving Considerations for PET response criteria in solid tumors. Journal of Nuclear Medicine50 (Supplement 1) 122S\u2013150S. (https:\/\/doi.org\/10.2967\/jnumed.108.057307)10.2967\/jnumed.108.057307"},{"key":"bib45","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1210\/jc.2002-020312","article-title":"Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene","volume":"87","author":"Young","year":"2002","unstructured":"Young ALBaysal BEDeb AYoung Jr. WF2002Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. Journal of Clinical Endocrinology and Metabolism874101\u20134105. (https:\/\/doi.org\/10.1210\/jc.2002-020312)10.1210\/jc.2002-020312"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/29\/9\/ERC-21-0392.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/29\/9\/ERC-21-0392.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/29\/9\/ERC-21-0392.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:56:12Z","timestamp":1784555772000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/29\/9\/533-544\/25685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":45,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.1530\/erc-21-0392","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}